This is one of the most consequential questions in the peptide skincare space, and getting it wrong can result in FDA warning letters, FTC enforcement, or product seizure.
In the United States, topical cosmetics are regulated under the Federal Food, Drug, and Cosmetic Act (FD&C Act). A cosmetic claim must relate to appearance — how the product looks on or affects the surface of the skin — not to physiological function. The moment your claim implies a drug-like action (altering muscle activity, blocking nerve signals, changing biological processes), you've potentially reclassified your product as a drug, requiring a New Drug Application.
Safe cosmetic claim language for peptide creams includes: "visibly reduces the appearance of fine lines and wrinkles," "skin looks smoother and more youthful," "helps soften the look of expression lines," "supports a more refreshed complexion." These describe visible, aesthetic outcomes without implying biological mechanism.
Risky claim language includes: "relaxes facial muscles," "inhibits muscle contractions like Botox," "clinically proven to reduce wrinkle depth" (unless backed by a properly powered clinical study with full methodology disclosure), or any direct comparison to a prescription drug or medical procedure that implies equivalent mechanism of action.
The FTC additionally requires that any quantified efficacy claim ("reduces wrinkles by 47% in 4 weeks") be backed by competent and reliable scientific evidence — generally at least one well-controlled consumer use study or clinical trial. A manufacturer's internal test on 10 subjects is unlikely to satisfy this standard.
In the EU, the Cosmetic Claims Regulation (EC No 655/2013) requires that all claims be truthful, supported by evidence, honest, fair, and not misleading. The six common criteria assessment applies. "Botox alternative" as a claim is almost certainly non-compliant in the EU because it implies equivalence to a medical procedure.
In the UK post-Brexit, the equivalent CTPA guidelines apply and mirror EU standards closely.
California's Prop 65 is relevant if your formula contains any Prop 65-listed substances at or above safe harbor levels — confirm with your manufacturer and a regulatory consultant.
The practical guidance: retain a cosmetic regulatory consultant before finalizing your label and marketing copy. A one-time review ($500–$2,000) is far cheaper than an FDA warning letter response. AJ Cosmo Labs connects founders with experienced cosmetic formulators and regulatory consultants who can review claim language as part of your product development workflow.
Read the full guide on Private Label Peptide Botox Alternative Cream Manufacturer →